Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Grey Matters Health (OTC: AGNPF) announced it has received a Radioactive Materials License from the State of Florida for its flagship NovaScan Neuroimaging Clinics™ location in Davie, Florida. The NovaScan clinic is scheduled to open by September 30, following this final major regulatory step.
Grey Matters Health (OTC: AGNPF) signed a professional services agreement with ProScan Reading Services, a division of ProScan Imaging, to interpret brain PET scans from its flagship NovaScan Neuroimaging Clinics™ site in Davie, Florida, scheduled to open by September 30. ProScan’s fellowship-trained, board-certified subspecialty radiologists will remotely read PET images for Alzheimer’s disease, frontotemporal dementia, Parkinson’s, Lewy body dementia, and select neuro-oncology cases, using the FDA-cleared CareMiBrain™ seated brain PET scanner, which delivers high-resolution images with about 25% less radiation exposure. NovaScan will offer beta-amyloid plaque imaging, covered by Medicare, Medicaid and private insurance for eligible 65+ patients, and ProScan will provide standardized Centiloid-scale reports. According to Grey Matters, this Davie clinic is the first step in a planned national NovaScan network in the U.S.
Grey Matters Health (OTC: AGNPF) has appointed radiologist Dr. Jayson A. Lord, MD as Medical Director of its first dedicated NovaScan Neuroimaging ClinicsTM site, scheduled to open in September 2026 in Davie, Florida. The clinic, located in the HCA Florida University Medical Office Building, will use the U.S. FDA-cleared CareMiBrain™ seated PET brain scanner to provide brain-dedicated PET imaging for Alzheimer’s disease and other neurodegenerative and select neuro-oncology indications, with beta-amyloid scans covered by Medicare, Medicaid and private insurance for eligible patients. Grey Matters also granted 885,000 restricted share units to executives, employees and directors, vesting on the grant date.
Grey Matters Health (OTC: AGNPF) plans to open its flagship NovaScan Neuroimaging ClinicsTM site next month in Davie, Florida, targeting a first brain PET scan by September 30, 2026. The clinic, located in the HCA Florida University Medical Office Building, will be the first U.S. site dedicated to brain PET imaging for Alzheimer’s disease and other neurodegenerative disorders.
The site will use the FDA-cleared CareMiBrain seated brain PET scanner, which does not require CT and is described as providing about 25% less radiation exposure. Brain PET scans for beta-amyloid plaque in patients 65+ are covered by Medicare, Medicaid and private insurance. Grey Matters’ business plan is to build a national NovaScan clinic network across the U.S.
Grey Matters Health (OTC: AGNPF) has taken delivery of its first brain-dedicated PET scanner for the flagship NovaScan Neuroimaging clinic in Davie, Florida, on the HCA Florida University Hospital campus.
The FDA-cleared CareMiBrain system provides brain-only PET imaging with about 25% less radiation, supports Alzheimer’s beta-amyloid detection, is reimbursed for patients 65+, and will also serve other neurodegenerative and select neuro-oncology indications. The clinic will be the first in the U.S. focused on brain-only PET scans and targets a stated billion-dollar Alzheimer’s imaging and treatment market. Licences, construction and system installation are underway, with opening and referral dates to be announced.
Grey Matters Health (OTCQB: AGNPF) signed a non-binding LOI with Catalyst MedTech to provide a minimum of 200 brain PET scans for an upcoming Alzheimer’s clinical trial at its planned second NovaScan clinic in Tampa, Florida.
The Tampa clinic is targeted for Q4 2026, following the first Davie, Florida brain PET clinic, planned to open in Q3. NovaScan clinics will use the FDA-cleared CareMiBrain system, designed for dedicated brain PET imaging with about 25% lower radiation exposure versus conventional PET/CT.
Algernon Health (OTCQB: AGNPF) announced that effective April 21, 2026 it will change its corporate name to Grey Matters Health Inc. and complete a 10:1 consolidation of its Class A common shares.
The company will begin trading under the new CSE symbol GREY, with new CUSIP 397884107 and ISIN CA3978841078. Post-consolidation issued and outstanding common shares will be approximately 5,418,243. Letters of transmittal will be mailed to registered shareholders; no action is required by non-registered shareholders. Outstanding preferred shares, warrants, stock options and restricted share units will be adjusted per their terms.
Algernon Health (OTCQB: AGNPF) plans to change its name to Grey Matters Health Inc. and reserved the CSE symbol GREY. The company proposes a 10:1 share consolidation, reducing 54,182,431 shares to ~5,418,243 post-consolidation.
The rebrand aligns with a shift toward Alzheimer’s diagnostic services and plans to open NovaScan Neuroimaging Clinics, with the first clinic announced at HCA Florida University Hospital in Davie. The company retains drug-development assets, including a 20% stake in Seyltx and intellectual property for DMT stroke and CKD programs. Name change and consolidation require CSE approval.
Algernon Health (OTCQB: AGNPF) unveiled NovaScan Neuroimaging Clinics as the brand for its planned U.S. brain PET network, launching at HCA Florida University Medical Offices in Davie, FL.
Clinics will feature the U.S. FDA-cleared CareMiBrain™ standalone PET scanner, offering dedicated brain imaging, 25% less radiation versus PET/CT, and support for dementia, epilepsy, Parkinson’s, MS, brain cancer and clinical trials. An official opening date and referral start will be announced soon.
Algernon Health (OTCQB: AGNPF) will open its first U.S. brain-dedicated PET scanning clinic on March 23, 2026, at the HCA Florida University Medical Office Building in Davie, Florida. Algernon USA signed a five-year lease with a renewal option and plans multiple U.S. clinics.
The clinic will use the U.S. FDA-cleared CareMiBrain™ standalone PET system (no integrated CT), which the company says reduces patient radiation by ~25%, and targets Alzheimer’s, dementia, epilepsy, neuro-oncology and movement disorders.